🇺🇸 FDA
Patent

US 11992528

Compositions and methods for conjugating activatable antibodies

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 11992528 (Compositions and methods for conjugating activatable antibodies) held by CytomX Therapeutics, Inc. expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CytomX Therapeutics, Inc.
Grant date
Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K47/68031, A61K47/6851